Topic Archives: Gilead (GILD)

AB4 Vaccine Ignites “Fierce Bidding War” for “Small Texas Lab?”

Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]

Long Idea of the Year

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

Can this $5 Company rise 16,000% and “Eradicate Zika” like Sid Riggs teases?

The folks at Money Map/Money Morning have really taken the “most aggressive advertisers” mantle from the other Agora affiliates of late — we can pretty much count on a new promotional campaign from this publisher becoming the “most asked about” pitch by our readers almost instantly, whether it’s Michael Robinson or Keith Fitz-Gerald or Dr. […]

Cyto Who?

[Ed. Note: Dr. KSS is an MD and PhD who writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and recent comments here.] You’re probably getting it right by now—writing “2016” and not “2015.” […]

The Manchurian Candida

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and biography here.] “Many things you hear in this room are untrue.” (sign posted in Yale-New Haven Medical Center physician cafeteria) […]

The Postman Always Rings Nice

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can read his past articles, latest comments, and bio here.] We love when readers write in, and most of the questions, even though privately put, are […]

The Tao of Recro

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his past articles here.] “Who wants honey? As long as there’s some money?” —–“Cherub Rock,” Smashing Pumpkins, Siamese Dream (words and […]

CellCeutix: 23 Minutes with Leo Ehrlich

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see all of his past articles here.] “All non-denial denials. They doubt our ancestry, but they don’t say the story isn’t accurate.” —-from All the President’s […]

The Last Samurai Biotech

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]

The Zed Files

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]

Saving Jack Kerouac

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]

A Non-Statin Pill That Really Lowers Cholesterol, Blood Pressure and Inflammation without Side Effects Would be a Good Investment, Right?

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Gr8Full!

    $GILD (KITE); $EDIT related - Jakobovits abruptly exits Adicet; Stanford researchers uncover mechanistic details of ALS ...

  • Gr8Full!

    $GILD - And EndPoints from John Carroll TOP STORIES Searching for HIV cure, Gilead's new 'shock and kill' combo swat...

  • Avatar

    Gilead (GILD) Said Close to Pulling Trigger on Incyte (INCY) Takeover - StreetInsider https://www.streetinsider.com/H...

  • SoGiAm

    $GILD np - Almost two years to the day since Gilead $GILD struck a deal worth up to $470 million for Phenex’s FXR agon...

  • Avatar

    Re $GLPG - this from Fierce Biotech: "Galapagos ($GLPG) CEO Onno van de Stolpe has confirmed that the standstill agreeme...

  • Avatar

    $GILD (just in): Gilead scraps a PhII/III study early as drug flops against ulcerative colitis by john carroll Sept...

  • Avatar

    $GILD just in - Gilead scraps a PhII/III study early as drug flops against ulcerative colitis by john carroll Septe...

  • Avatar

    $GILD $GLPG: Gilead tackles a big PhIII program for blockbuster hopeful filgotinib, acquired from Galapagos (GLPG) mo...

  • Dr. KSS MD PhD

    Is someone from Piper Jaffray reading us? We've said for a couple of months that Gilead ($GILD) should break up into a v...

  • Avatar

    $RGLS (long) http://tinyurl.com/z6qeum9 AbbVie ($ABBV) is touting impressive cure rates for its new daily hep C combo...

  • Avatar

    Leerink bullish on Gilead (GILD). http://blogs.barrons.com/stockstowatchtoday/2016/03/07/why-gilead-sciences-could-ga...

  • sogiam

    $ZFGN, GNFT-"Do you think anyone will give a flying faffola about NASH remedies like obeticholic acid from Intercept ($I...

  • Avatar

    Nice article on Gilead (GILD). One might wonder if Regulus (RGLS) is on their radar. http://www.fool.com/investing/gene...

  • Avatar

    Hi Everyone, I want to just take a minute to say I think the bottom is in on Gilead ($GILD). It's butting up against e...

  • Avatar

    Cramer 4 Biotech's to buy for 2016 include Gilead (GILD) and Celgene (CELG). http://www.cnbc.com/2015/12/23/cramer-bi...

  • Avatar

    Why Gilead ($GILD) and Roche ($RHHBY) Should Take a Good Look at Clovis Oncology ($CLVS) as Possible M&A Target By Mark ...

  • Avatar

    $GILD $ACHN Gilead (GILD) Rumored to be Eying Achillion (ACHN)...Again http://www.biospace.com/news_story.aspx?StoryI...

  • Avatar

    Thanks so much Doc. Gilead (GILD) is boss. Cheers,Glenn...

  • Dr. KSS, MD PhD

    Frank...I am sure it has been considered in the loftier echelons at Gilead. GILD is rapidly trying to decide whether to ...

  • sogiam

    GILD-M&A soon maybe? Gilead More Open to Deals -- Market Talk 4/3/15 4:46 PM ET (Dow Jones) -- Gilead (GILD) Chief Oper...

  • Avatar

    Interesting trade put on Gilead (GILD) today. Investor could lose up to 1.2 million if GILD does not clear 111.50 in two...

  • Avatar

    Gilead (GILD) warns after patient dies on its HEP C drug Harvoni or Sovaldi with the heart treatment amiodarone.Nine pa...

  • Avatar

    Great article. Noticed the recent link between Arrowhead (ARWR) and Gilead (GILD). In your opinion, could a combination...

  • Avatar

    More good news on Gilead (GILD), posted on Barron's blog today: Gilead Sciences: Another Big Jump in Hep-C Prescription...

  • Avatar

    John Carroll (Fierce) reported this morning that, in a surprise move, Bristol-Myers drops U.S. approval plans for hep C ...

  • Avatar

    Currently my two favorite big upside safer small biotechs are Sinovac (SVA) and Cellceutix (CTIX). Two much safer big b...

  • Dr. KSS, MD PhD

    Gilead (GILD) earnings beat: $ 2.36 EPS versus mean analyst estimate of $1.73 EPS. Blow out! 3.4B Sovaldi sale...

  • Avatar

    Check out this very positive Barron's article on Gilead (GILD): http://www.forbes.com/sites/kenkam/2014/06/06/how-gilea...

  • Dr. KSS, MD PhD

    A digression to remind people that Gilead (GILD), large cap biotech or not, remains a screaming buy in my opinion. For t...

  • frank archambeau

    Siva; I recently noticed that Gilead GILD is a sponsor & advertiser of Nascar pushing their hepC product. Unlikely pairi...

  • karmaswimswami

    To Winston Faust: One thing I think everybody here should do is use whatever software or site you use to track stocks, a...

  • frank archambeau

    DR KSS I well may have missed comments if you have already covered but is something going on at Gilead GILD. I boug...

  • Avatar

    Gilead (GILD)...

  • Avatar

    That one is Gilead (GILD), though the stock recently tanked and is crawling back from the dead!...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch